Natural Products and Derivatives Targeting at Cancer Energy Metabolism: A Potential Treatment Strategy

Abstract

In the 1920s, Dr Otto Warburg first suggested the significant difference in energy metabolism between malignant cancer cells and adjacent normal cells. Tumor cells mainly adopt the glycolysis as energy source to maintain tumor cell growth and biosynthesis under aerobic conditions. Investigation on energy metabolism pathway in cancer cells has aroused the interest of cancer researchers all around the world. In recent years, plentiful studies suggest that targeting the peculiar cancer energy metabolic pathways, including glycolysis, mitochondrial respiration, amino acid metabolism, and fatty acid oxidation may be an effective strategy to starve cancer cells by blocking essential nutrients. Natural products (NPs) are considered as the “treasure trove of small molecules drugs” and have played an extremely remarkable role in the discovery and development of anticancer drugs. And numerous NPs have been reported to act on cancer energy metabolism targets. Herein, a comprehensive overview about cancer energy metabolism targets and their natural-occurring inhibitors is prepared.

Keywords

cancer energy metabolism / cancer therapy / natural products / binding targets / inhibitors

References

[1] BakerDD, ChuM, OzaU, et al.. The value of natural products to future pharmaceutical discovery. Nat Prod Rep, 2007, 24(6): 1225-1244

[2] HarveyAL. Natural products in drug discovery. Drug Discov Today, 2008, 13(19–20): 894

[3] AminAR, KucukO, KhuriFR, et al.. Perspectives for cancer prevention with natural compounds. J Clin Oncol, 2009, 27(16): 2712-2725

[4] Vander HeidenMG, CantleyLC, ThompsonCB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324(5930): 1029-1033

[5] GanapathyV, ThangarajuM, PrasadPD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Therapeut, 2009, 121(1): 29-40

[6] GodoyA, UlloaV, RodriguezF, et al.. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol, 2006, 207(3): 614-627

[7] MachedaML, RogersS, BestJD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol, 2005, 202(3): 654-662

[8] DengD, XuC, SunP, et al.. Crystal structure of the human glucose transporter GLUT1. Nature, 2014, 510(7503): 121-125

[9] HoYY, YangH, KlepperJ, et al.. Glucose transporter type 1 deficiency syndrome (Glut1DS): mthylxanthines potentiate GLUT1 haploinsufficiency in vitro. Pediatr Res, 2001, 50(2): 254-260

[10] SteinfelderHJ, Pethö-SchrammS. Methylxanthines inhibit glucose transport in rat adipocytes by two independent mechanisms. Biochem Pharmacol, 1990, 40(5): 1154-1157

[11] OjedaP, PérezA, OjedaL, et al.. Noncompetitive blocking of human GLUT1 hexose transporter by methylxanthines reveals an exofacial regulatory binding site. Am J Physiol Cell Physiol, 2012, 303(5): C530

[12] KrasnovGS, DmitrievAA, LakuninaVA, et al.. Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets, 2013, 17(10): 1221-1233

[13] PatraKC, WangQ, BhaskarPT, et al.. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell, 2013, 24(3): 399

[14] BaoF, YangK, WuC, et al.. New natural inhibitors of hexokinase 2 (HK2): steroids from ganoderma sinense. Fitoterapia, 2018, 125: 123-129

[15] JacquinMA, ChicheJ, ZuninoB, et al.. GAPDH binds to active Akt, leading to Bcl-X_L increase and escape from caspase-independent cell death. Cell Death Differ, 2013, 20(8): 1043

[16] Ganapathy-KanniappanS, KunjithapathamR, GeschwindJF. Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget, 2012, 3(9): 940

[17] KrasnovGS, DmitrievAA, SnezhkinaAV, et al.. Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target. Expert Opin Ther Targets, 2013, 17(6): 681-693

[18] ItohY, KodamaK, FuruyaK, et al.. A new sesquiterpene antibiotic, heptelidic acid. Producing organisms, fermentation, isolation and characterization. J Antibiot, 1980, 33(5): 468

[19] RahierNJ, MolinierN, LongC, et al.. Anticancer activity of koningic acid and semisynthetic derivatives. Bioorg Med Chem Lett, 2015, 23(13): 3712-3721

[20] EverseJ, KaplanNO. Lactate dehydrogenases: structure and function. Adv Enzymol Relat Areas Mol Biol, 1973, 37: 61-133

[21] ManerbaM, VettrainoM, FiumeL, et al.. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. Chemmedchem, 2012, 7(2): 311-317

[22] FarabegoliF, VettrainoM, ManerbaM, et al.. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur J Pharm Sci, 2012, 47(4): 729

[23] TakadaM, NakamuraY, KoizumiT, et al.. Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. Pancreas, 2002, 25(1): 45-48

[24] ZhangL, PangE, LooR, et al.. Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF-II cells. Proteomics, 2011, 11(24): 4638

[25] LuQY, ZhangL, YeeJK, et al.. Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer cells. Metabolomics, 2015, 11(1): 71-80

[26] SonveauxP, CopettiT D, SaedeleerCJ, et al.. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One, 2012, 7(3): e33418

[27] SonveauxP, VegranF, SchroederT, et al.. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest, 2008, 118(12): 3930-3942

[28] MorrisME, ZhangS. Flavonoid–drug interactions: effects of flavonoids on ABC transporters. Life Sci, 2006, 78(18): 2116-2130

[29] WangQ, MorrisME. Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos, 2007, 35(2): 201-208

[30] ZhangS, MorrisME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther, 2003, 304(3): 1258-1267

[31] ShimCK, CheonEP, KangKW, et al.. Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. J. Pharm. Pharmacol, 2007, 59(11): 1515-1519

[32] JoladSD, HoffmannJJ, SchramKH, et al.. Structures of zeylenol and zeylena, constituents of Uvaria zeylanica (annonaceae). J Org Chem, 1982, 46: 4267-4272

[33] MotoyamaT, YabunakaH, MiyoshiH. Essential structural factors of acetogenins, potent inhibitors of mitochondrial complex I. ACS Med Chem Lett, 2002, 12(16): 2089-2092

[34] Schlie-GuzmánMA, García-CarrancáA, González-EsquincaAR. In vitro and in vivo antiproliferative activity of laherradurin and cherimolin-2 of Annona diversifolia Saff. Phytother Res, 2010, 23(8): 1128-1133

[35] YuanSS, ChangHL, ChenHW, et al.. Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase-3-related pathway. Life Sci, 2003, 72(25): 2853-2861

[36] DePN, CautainB, MelguizoA, et al.. Mitochondrial complex I inhibitors, acetogenins, induce HepG2 cell death through the induction of the complete apoptotic mitochondrial pathway. J Bioenerg Biomembr, 2013, 45(1–2): 153-164

[37] HuiYH, RupprechtJK, LiuYM, et al.. Bullatacin and bullatacinone: two highly potent bioactive acetogenins from Annona bullata. J Nat Prod, 1989, 52(3): 463-477

[38] MorréDJ, DeCR, FarleyC, et al.. Mode of action of bullatacin, a potent antitumor acetogenin: Inhibition of NADH oxidase activity of HELA and HL-60, but not liver, plasma membranes. Life Sci, 1995, 56(5): 343-348

[39] WolvetangEJ, JohnsonKL, KrauerK, et al.. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett, 1994, 339(1–2): 40

[40] ChiuHF, ChihTT, HsianYM, et al.. Bullatacin, a potent antitumor Annonaceous acetogenin, induces apoptosis through a reduction of intracellular cAMP and cGMP levels in human hepatoma 2.2.15 cells. Biochem. Pharmacol, 2003, 65(3): 319-327

[41] MeyerKJ, SinghAJ, CameronA, et al.. Mitochondrial genome-knockout cells demonstrate a dual mechanism of cction for the electron transport Complex I inhibitor mycothiazole. Mar Drugs, 2012, 10(4): 900-917

[42] CrewsP, KakouY, QuinoaE. Mycothiazole, a polyketide heterocycle from a marine sponge. J Am Chem Soc, 1988, 110(13): 4365-4368

[43] LiuQ, ShuX, SunA, et al.. Plant-derived small molecule albaconol suppresses LPS-triggered proinflammatory cytokine production and antigen presentation of dendritic cells by impairing NF-kappaB activation. Int Immunopharmacol, 2008, 8(8): 1103-1111

[44] DengQ, YuX, XiaoL, et al.. Neoalbaconol induces energy depletion and multiple cell death in cancer cells by targeting PDK1-PI3-K/Akt signaling pathway. Cell Death Dis, 2013, 19(4): e804

[45] SchulteML, FuA, ZhaoP, et al.. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med, 2018, 24(2): 194-202

[46] SchulteML, HightMR, AyersGD, et al.. Non-invasive glutamine pet reflects pharmacological inhibition of BRAF(V600E) in vivo. Mol Imaging Biol, 2017, 19(3): 421-428

[47] MatesJM, SeguraJ M-R M, et al.. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med, 2013, 13(4): 514-534

[48] HartwickEW, CurthoysNP. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase. J Enzym Inhib Med Ch, 2012, 27(6): 861

[49] WangJB, EricksonJW, FujiR, et al.. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell, 2010, 18(3): 207

[50] WuC, ZhengM, GaoS, et al.. A natural inhibitor of kidney-type glutaminase: a withanolide from with potent anti-tumor activity. Oncotarget, 2017, 8(69): 113 516-113 530

[51] ChengL, WuCR, ZhuLH, et al.. Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor. ACS Med Chem Lett, 2017, 27(5): 1243

[52] LiC, AllenA, KwaghJ, et al.. Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. J Biol Chem, 2006, 281(15): 10 214-10 221

[53] LiC, LiM, ChenP, et al.. Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site. J Biol Chem, 2011, 286(39): 34 164-34 174

[54] LiM, LiC, AllenA, et al.. Glutamate dehydrogenase: structure, allosteric regulation, and role in insulin homeostasis. Neurochem Res, 2014, 39(3): 433-445

[55] AnglinJ, ZavarehRB, SanderPN, et al.. Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. ACS Med Chem Lett, 2018, 28(16): 2675-2678

[56] HoltMC, AssarZ B Z R, et al.. Biochemical characterization and structure-based mutational analysis provide insight into the binding and mechanism of action of novel aspartate aminotransferase Inhibitors. Biochemistry, 2018, 57(47): 6604-6614

[57] ThornburgJM, NelsonKK, ClemBF, et al.. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res, 2008, 10(5): R84

[58] SunW, LuanS, QiC, et al.. Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism. Cell Commun Signal, 2019, 17(1): 111

[59] GuoJ, GuX, ZhengM, et al.. Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase. CS Med Chem Lett, 2019, 87: 16-22

[60] XuY, BarringerS. Comparison of volatile release in tomatillo and different varieties of tomato during chewing. J Food Sci, 2010, 75(4): C352-358

[61] ZhengM, GuoJ, XuJ, et al.. Ixocarpalactone A from dietary tomatillo inhibits pancreatic cancer growth by targeting PHGDH. Food Funct, 2019, 10(6): 3386-3395

[62] DonnerJ, ReckM, BergmannS, et al.. The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target. Sci Rep, 2016, 6: 29677

[63] KunzeB, ReckM, DotschA, et al.. Damage of Streptococcus mutans biofilms by carolacton, a secondary metabolite from the myxobacterium Sorangium cellulosum. BMC Microbiol, 2010, 10: 199

[64] JansenR, IrschikH, HuchV, et al.. Carolacton-a macrolide ketocarbonic acid that reduces biofilm formation by the caries-and endocarditis-associated bacterium streptococcus mutans. European J Org Chem, 2010, 7: 1284-1289

[65] FuC, SikandarA, DonnerJ, et al.. The natural product carolacton inhibits folate-dependent C1 metabolism by targeting FolD/MTHFD. Nat Commun, 2017, 8(1): 1529

[66] Sanchez-MacedoN, FengJ, FaubertB, et al.. Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell Death Differ, 2013, 20(4): 659-668

[67] RicciardiMR, MirabiliiS, AllegrettiM, et al.. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood, 2015, 126(16): 1925-1929

[68] TsengCC, NoordaliH, SaniM, et al.. Development of fluorinated analogues of perhexiline with improved pharmacokinetic properties and retained efficacy. J Med Chem, 2017, 60(7): 2780-2789

[69] KhwairakpamAD, ShyamanandaMS, SailoBL, et al.. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Cancer Drug Targets, 2015, 16(2): 156-163

[70] FassinaP, SchererA F, TerezinhaZ V, et al.. The effect of garcinia cambogia as coadjuvant in the weight loss process. Nutr Hosp, 2015, 32(6): 2400-2408

[71] WatsonJA, FangM, LowensteinJM. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch Biochem Biophys, 1969, 135(1): 209-217

[72] LiuY, JiH, DongJ, et al.. Antioxidant alkaloid from the South China Sea marine sponge Iotrochota sp. Z Naturforsch C J Biosci, 2008, 63(9–10): 636-63

[73] OleynekJJ, BarrowCJ, BurnsMP, et al.. Anthrones, naturally occurring competitive inhibitors of adenosine-triphosphate-citrate lyase. Drug Dev Res, 2010, 36(1): 35-42

[74] YamamotoY, KiriyamaN, ArahataS. Studies on the metabolic products of Aspergillus fumigatus (J-4). Chemical structure of metabolic products. Chem Pharm Bull, 1968, 16(2): 304

[75] BarrowCJ, OleynekJJ, MarinelliV, et al.. Antimycins, inhibitors of ATP-citrate lyase, from a streptomyces sp. J Antibiot, 2010, 50(9): 729-733

[76] GaoY, IslamMS, TianJ, et al.. Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. Cancer Lett, 2014, 349(1): 15-25

[77] KoernerSK, HanaiJI, BaiS, et al.. Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase. Eur J Med Chem, 2017, 126: 920-928

[78] DengZ, WongNK, GuoZ, et al.. Dehydrocurvularin is a potent antineoplastic agent irreversibly blocking ATP-citrate lyase: evidence from chemoproteomics. Chem Commun, 2019, 55(29): 4194-4197

[79] ChajesV, CambotM, MoreauK, et al.. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res, 2006, 66(10): 5287-5294

[80] KoenB, EllenDS, GuidoV, et al.. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res, 2005, 65(15): 6719-6725

[81] SvenssonRU, ShawRJ. Lipid synthesis is a metabolic liability of non-small cell lung cancer. Cold Spring Harb Symp Quant Biol, 2016, 81: 93-103

[82] GerthK, PradellaS, PerlovaO, et al.. Myxobacteria: proficient producers of novel natural products with various biological activities-past and future biotechnological aspects with the focus on the genus Sorangium. J Biotechnol, 2003, 106(2–3): 233-253

[83] BeckersA, OrganeS, TimmermansL, et al.. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res, 2007, 67(17): 8180-8187

[84] OmuraS. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev, 1976, 40(3): 681-697

[85] KuhajdaFP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition, 2000, 16(3): 202-208

[86] PizerES, ChrestFJ, DiGiuseppeJA, et al.. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res, 1998, 58(20): 4611-4615

[87] MenendezJA, VellonL, LupuR. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol, 2005, 16(8): 1253-1267

[88] WangX, TianW. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun, 2001, 288(5): 1200-1206

[89] WangX, SongKS, GuoQX, et al.. The galloyl moiety of green tea catechins is the critical structural feature to inhibit fatty-acid synthase. Biochem Pharmacol, 2003, 66(10): 2039

[90] WangX, TianW. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Bioph Res Co, 2001, 288(5): 1200-1206

[91] BrusselmansK, VrolixR, VerhoevenG, et al.. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem, 2005, 280(7): 5636-5645

[92] LvZD, LiuXP, ZhaoWJ, et al.. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Patho, 2014, 7(6): 2818-2824

[93] GuanF, DingY, ZhangY, et al.. Curcumin suppresses proliferation and migration of MDA-MB-231 breast cancer cells through autophagy-dependent Akt degradation. PLoS One, 2016, 11(1): e0146553

[94] YounesianO, KazerouniF, OmraniD, et al.. Effect of curcumin on fatty acid synthase expression and enzyme activity in breast cancer cell line SKBR3. Int J Cancer Manag, 2017

[95] LeeKH, LeeM C E Y, et al.. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis. Mol Med Rep, 2017, 15(4): 2163